[8-K] Ardent Health, Inc. Reports Material Event

Rhea-AI Filing Summary

On 5 Aug 2025, KULR Technology Group, Inc. filed a Form 8-K (Item 7.01) to furnish a press release announcing that it will host a conference call on 14 Aug 2025 at 4:30 p.m. ET to discuss financial results for the quarter ended 30 Jun 2025. The press release is attached as Exhibit 99.1. The company states that the information is being “furnished,” not “filed,” and therefore is not subject to Section 18 liability or automatically incorporated by reference into other SEC filings. KULR also reminds investors that it disseminates material information through its website and multiple social-media platforms, including Twitter, LinkedIn, Facebook, TikTok, Instagram and YouTube.

Insights

Financial Analyst

TL;DR: Routine Reg FD filing; schedules Q2 earnings call—no financial data, neutral impact.

This 8-K contains no revenue, EPS or guidance figures and introduces no strategic initiative. Its sole purpose is to alert the market to KULR’s upcoming Q2 2025 conference call. Consequently, it neither strengthens nor weakens the investment thesis at this stage. Material implications—if any—will depend on the results released on 14 Aug. Impact assessment: administrative, not price-moving.

FALSE000175665500017566552025-08-052025-08-05

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
	FORM	8-K
CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

Ardent Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-42180	61-1764793
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

340 Seven Springs Way, Suite 100, Brentwood, Tennessee		37027
(Address of Principal Executive Offices)		(Zip Code)

(615) 296-3000

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under

any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $.01 par value per share		ARDT		New York Stock Exchange

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act

of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition

period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act.  o

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2025, Ardent Health, Inc. issued a press release announcing its financial results for the second quarter ended

June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is

incorporated herein by reference.

The information in this Current Report on Form 8-K furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be

deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically provided in any such

filing.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits:

Exhibit No.	Exhibit Description
Exhibit 99.1	Press Release, dated August 5, 2025
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed

on its behalf by the undersigned hereunto duly authorized.

Dated: August 5, 2025	ARDENT HEALTH, INC.
	By:	/s/ Alfred Lumsdaine
	Name:	Alfred Lumsdaine
	Title:	Executive Vice President, Chief Financial Officer

FAQ

When will KULR (KULR) hold its Q2 2025 earnings conference call?

The call is scheduled for August 14, 2025 at 4:30 p.m. ET.

What exhibit contains the related press release in KULR’s Form 8-K?

The press release is furnished as Exhibit 99.1.

Is the information in this 8-K considered “filed” under the Exchange Act?

No. It is being furnished, not filed, and is not subject to Section 18 liability.

Under which item of Form 8-K did KULR disclose the conference call?

The disclosure appears under Item 7.01 – Regulation FD.

Which social-media channels does KULR use for investor updates?

KULR cites Twitter, LinkedIn, Facebook, TikTok, Instagram and YouTube as additional disclosure platforms.